BOSTON, May 08, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the
development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it has completed
enrollment in its pivotal Phase 3 clinical study evaluating oral-only omadacycline for the treatment of Acute Bacterial Skin and
Skin Structure Infections (ABSSSI). The Company expects to report top-line data from this study in mid-July. This study is designed
to assess the efficacy and safety of once-daily oral-only omadacycline compared with twice-daily oral-only linezolid in subjects
with ABSSSI.
“The completion of enrollment of our Phase 3 oral-only study is another important milestone for Paratek and moves us closer to
providing a new, well-tolerated, broad-spectrum once-daily oral-only antibiotic to treat serious community-acquired skin
infections,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer, Paratek. “Oral antibiotic
therapies for community-acquired skin infection are advantageous as they can eliminate the need for hospital stays, have the
potential to reduce the overall cost of treatment and limit a patient’s exposure to secondary infection in the hospital setting.
Unfortunately, what we are seeing is that more and more people are being admitted to the hospital for skin infections that are
resistant to the existing, older oral agents, which underscores the need for a new, effective, broad spectrum oral agent with MRSA
coverage for community-acquired skin infections.”
The Phase 3, randomized, double-blind, multi-center study in adults with moderate to severe ABSSSI compared the safety and
efficacy of once-daily oral omadacycline to twice-daily oral linezolid. The study is designed to enroll approximately 700 patients
at approximately 50 U.S. centers. For the purposes of regulatory filings in the United States, the primary efficacy endpoint
defined in the protocol is the number of subjects with clinical success at the early clinical response assessment 48-72 hours after
the first dose of study drug. For regulatory filings in the European Union, the primary endpoint will be clinical response at
the post therapy evaluation, also known as ‘test of cure’. Other efficacy outcome measurements include investigator assessment
of clinical response, overall survival and resolution or improvement of signs and symptoms at the post-treatment evaluation visit
(7-14 days after the last day of therapy). In addition, safety and tolerability as assessed by treatment-emergent adverse events,
vital sign measurements, ECGs, and laboratory values will be assessed.
About Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)
ABSSSI is responsible for more than 750,000 hospitalizations per year (latest data available, 2011), representing a
17.3% increase in hospitalized ABSSSI patients from 2005 to 2011.
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of
innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, when
approved, will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against
Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad spectrum
antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial
infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary
tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to
prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status
by the U.S. Food and Drug Administration for the target indications.
In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin
structure infections (ABSSSI) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily oral
omadacycline compared to linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration study in
community-acquired bacterial pneumonia (CABP) demonstrating the efficacy and general safety and tolerability of IV to once-daily
oral omadacycline compared to moxifloxacin. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of
omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. This study completed enrollment in May
2017 and top-line data are expected in mid-July. The Company plans to submit its new drug application (NDA) in the U.S. as early as
the first quarter of 2018 with an EMA submission later in 2018.
In addition to its Phase 3 program for omadacycline, a Phase 1B study in uncomplicated urinary tract infections (UTI) was
initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016. The Company plans to begin
enrolling patients in a proof-of-concept Phase 2 study of omadacycline in acute pyelonephritis, the most common subset of
complicated urinary tract infections, as early as December 2017.
In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of
omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance including plague and
anthrax.
In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co., Ltd., entered into a
License and Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license to develop,
manufacture, and commercialize omadacycline in the People’s Republic of China, Hong Kong, Macau and Taiwan, for all human
therapeutic and preventative uses, other than biodefense. Zai will be responsible for the development, manufacturing and
commercialization of the licensed product in the licensed territory, at its sole cost with certain assistance from the Company.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow spectrum
tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the
community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all
ex-U.S. rights. Allergan and Paratek reported positive results from two identical Phase 3 registration studies of sarecycline for
the treatment of moderate to severe acne vulgaris in March 2017. Allergan has publicly announced plans to submit an NDA in the
U.S. in the second half of 2017.
For more information, visit www.paratekpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to our overall strategy, product
candidates, clinical studies, prospects, potential and expected results, including statements about the timing of advancing
omadacycline and otherwise preparing for clinical studies, the timing of enrollment in our clinical studies and our reporting of
the results of such studies, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients
suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline
providing broad-spectrum activity, and our ability to obtain regulatory approval of omadacycline All statements, other than
statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as
"advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of
similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and
uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections
disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our
actual results and the timing of events could differ materially from those included in such forward-looking statements as a result
of these risks and uncertainties. These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual
Report on Form 10-K for the year ended December 31, 2016, and our other filings with the Securities and Exchange Commission.
We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained
herein.
CONTACTS: Media Relations: Michael Lampe (484) 575-5040 michael@scientpr.com Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568
